> top > docs > PMC:7205724 > spans > 20480-23259 > annotations

PMC:7205724 / 20480-23259 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
693 20-25 Species denotes human Tax:9606
696 160-169 Species denotes SARS-CoV2 Tax:2697049
697 170-179 Disease denotes infection MESH:D007239
713 818-819 Gene denotes S Gene:43740568
714 805-806 Gene denotes S Gene:43740568
715 662-663 Gene denotes S Gene:43740568
716 603-604 Gene denotes S Gene:43740568
717 591-592 Gene denotes S Gene:43740568
718 459-460 Gene denotes S Gene:43740568
719 260-275 Species denotes transgenic mice Tax:10090
720 293-298 Species denotes human Tax:9606
721 341-344 Species denotes rat Tax:10116
722 452-458 Species denotes SARS-2 Tax:2697049
723 597-602 Species denotes SARS2 Tax:2697049
724 656-661 Species denotes SARS2 Tax:2697049
725 811-817 Species denotes SARS-2 Tax:2697049
726 546-564 Disease denotes decreased syncytia MESH:D002303
727 624-630 CellLine denotes VeroE6 CVCL:0574
729 889-894 Species denotes human Tax:9606
739 1187-1191 Gene denotes ACE2 Gene:59272
740 1321-1325 Gene denotes ACE2 Gene:59272
741 1274-1275 Gene denotes S Gene:43740568
742 1073-1074 Gene denotes S Gene:43740568
743 1060-1061 Gene denotes S Gene:43740568
744 1022-1023 Gene denotes S Gene:43740568
745 1000-1001 Gene denotes S Gene:43740568
746 1015-1021 Species denotes SARS-2 Tax:2697049
747 1066-1072 Species denotes SARS-2 Tax:2697049
750 1404-1407 Gene denotes IL6 Gene:3569
751 1422-1440 Disease denotes hyper inflammation MESH:D007249
760 1815-1823 Species denotes children Tax:9606
761 1499-1504 Species denotes human Tax:9606
762 1441-1452 Chemical denotes Tocilizumab MESH:C502936
763 1572-1591 Disease denotes autoimmune diseases MESH:D001327
764 1635-1655 Disease denotes rheumatoid arthritis MESH:D001172
765 1657-1677 Disease denotes giant cell arteritis MESH:D013700
766 1679-1722 Disease denotes polyarticular juvenile idiopathic arthritis MESH:D001171
767 1728-1768 Disease denotes systematic juvenile idiopathic arthritis MESH:D001171
772 1908-1916 Species denotes patients Tax:9606
773 1871-1882 Chemical denotes Tocilizumab MESH:C502936
774 1893-1904 Disease denotes lung injury MESH:D055370
775 1942-1950 Disease denotes COVID-19 MESH:C000657245
788 2123-2126 Gene denotes IL6 Gene:3569
789 2306-2309 Gene denotes CRP Gene:1401
790 1973-1981 Species denotes patients Tax:9606
791 2099-2107 Species denotes Patients Tax:9606
792 2367-2375 Species denotes patients Tax:9606
793 2064-2075 Chemical denotes Tocilizumab MESH:C502936
794 2163-2174 Chemical denotes tocilizumab MESH:C502936
795 2240-2246 Chemical denotes oxygen MESH:D010100
796 2434-2445 Chemical denotes tocilizumab MESH:C502936
797 1987-1995 Disease denotes COVID-19 MESH:C000657245
798 2324-2335 Disease denotes lung lesion MESH:D008171
799 2413-2419 Disease denotes deaths MESH:D003643
808 2708-2711 Gene denotes IL6 Gene:3569
809 2520-2528 Species denotes patients Tax:9606
810 2617-2625 Species denotes patients Tax:9606
811 2495-2506 Chemical denotes tocilizumab MESH:C502936
812 2586-2597 Chemical denotes Tocilizumab MESH:C502936
813 2554-2562 Disease denotes COVID-19 MESH:C000657245
814 2631-2639 Disease denotes COVID-19 MESH:C000657245
815 2666-2684 Disease denotes hyper inflammation MESH:D007249

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T149 37-45 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T150 74-81 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T151 224-232 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T152 299-313 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T153 352-366 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T154 491-499 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T155 631-636 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T156 895-899 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T157 900-905 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T158 1101-1109 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T159 1360-1369 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T160 1518-1526 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T161 1608-1616 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T162 1663-1667 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T163 1893-1897 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T164 2280-2290 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T165 2324-2328 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T166 2723-2731 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T21 895-899 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T22 1893-1897 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T23 2324-2328 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T151 160-164 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T152 170-179 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T153 441-445 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T154 452-456 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T155 586-590 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T156 645-649 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T157 800-804 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T158 811-815 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T159 995-999 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T160 1015-1019 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T161 1055-1059 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T162 1066-1070 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T163 1269-1273 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T164 1428-1440 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T165 1572-1591 Disease denotes autoimmune diseases http://purl.obolibrary.org/obo/MONDO_0007179
T166 1635-1655 Disease denotes rheumatoid arthritis http://purl.obolibrary.org/obo/MONDO_0008383
T167 1646-1655 Disease denotes arthritis http://purl.obolibrary.org/obo/MONDO_0005578
T168 1657-1677 Disease denotes giant cell arteritis http://purl.obolibrary.org/obo/MONDO_0008538
T169 1668-1677 Disease denotes arteritis http://purl.obolibrary.org/obo/MONDO_0043494
T170 1679-1722 Disease denotes polyarticular juvenile idiopathic arthritis http://purl.obolibrary.org/obo/MONDO_0018456
T171 1693-1722 Disease denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/MONDO_0011429
T172 1713-1722 Disease denotes arthritis http://purl.obolibrary.org/obo/MONDO_0005578
T173 1739-1768 Disease denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/MONDO_0011429
T174 1759-1768 Disease denotes arthritis http://purl.obolibrary.org/obo/MONDO_0005578
T175 1898-1904 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T176 1942-1950 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T177 1987-1995 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T178 2554-2562 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T179 2631-2639 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T180 2672-2684 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T238 18-19 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T239 20-25 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T240 102-103 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T241 142-147 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T242 190-199 http://purl.obolibrary.org/obo/CLO_0036932 denotes hybridoma
T243 293-298 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T244 515-516 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T245 536-544 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T246 624-636 http://purl.obolibrary.org/obo/CLO_0051719 denotes VeroE6 cells
T247 676-681 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T248 769-771 http://purl.obolibrary.org/obo/CLO_0050050 denotes S1
T249 889-894 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T250 895-899 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T251 895-899 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T252 900-923 http://purl.obolibrary.org/obo/CL_0001034 denotes cells as it is in vitro
T253 938-939 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T254 981-983 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T255 981-983 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T256 1181-1183 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T257 1181-1183 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T258 1303-1305 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T259 1303-1305 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T260 1390-1391 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T261 1482-1483 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T262 1484-1493 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humanized
T263 1499-1504 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T264 1663-1667 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T265 1893-1897 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T266 1893-1897 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T267 1965-1967 http://purl.obolibrary.org/obo/CLO_0050509 denotes 27
T268 2116-2117 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T269 2150-2152 http://purl.obolibrary.org/obo/CLO_0008426 denotes pg
T270 2324-2328 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T271 2324-2328 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T167 74-81 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T168 981-983 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T169 1181-1183 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T170 1303-1305 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T171 2163-2174 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T172 2240-2246 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T173 2434-2445 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T174 2495-2506 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T19 299-313 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T20 352-366 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T21 1220-1243 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes neutralizing antibodies http://purl.bioontology.org/ontology/MEDDRA/10058063
T22 2240-2275 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes oxygen saturation and normalization http://purl.bioontology.org/ontology/MEDDRA/10033322
T23 2723-2738 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes platelet counts http://purl.bioontology.org/ontology/MEDDRA/10035525

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T95 142-147 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T96 170-179 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T97 631-636 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T98 676-681 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T99 900-905 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T100 1583-1591 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T101 1663-1667 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T102 2216-2224 http://purl.obolibrary.org/obo/OGMS_0000020 denotes symptoms

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T109 74-81 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T110 2240-2246 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T195 20-25 Species denotes human NCBItxid:9606
T196 160-169 Species denotes SARS-CoV2 NCBItxid:2697049
T197 271-275 Species denotes mice NCBItxid:10095|NCBItxid:10088
T199 293-298 Species denotes human NCBItxid:9606
T200 341-344 Species denotes rat NCBItxid:10116|NCBItxid:10114
T202 441-445 Species denotes SARS NCBItxid:694009
T203 452-458 Species denotes SARS-2 NCBItxid:2697049
T204 586-590 Species denotes SARS NCBItxid:694009
T205 597-602 Species denotes SARS2 NCBItxid:2697049
T206 645-649 Species denotes SARS NCBItxid:694009
T207 656-661 Species denotes SARS2 NCBItxid:2697049
T208 800-804 Species denotes SARS NCBItxid:694009
T209 811-817 Species denotes SARS-2 NCBItxid:2697049
T210 889-894 Species denotes human NCBItxid:9606
T211 995-999 Species denotes SARS NCBItxid:694009
T212 1015-1021 Species denotes SARS-2 NCBItxid:2697049
T213 1055-1059 Species denotes SARS NCBItxid:694009
T214 1066-1072 Species denotes SARS-2 NCBItxid:2697049
T215 1269-1273 Species denotes SARS NCBItxid:694009
T216 1499-1504 Species denotes human NCBItxid:9606
T217 1942-1950 Species denotes COVID-19 NCBItxid:2697049
T218 1987-1995 Species denotes COVID-19 NCBItxid:2697049
T219 2554-2562 Species denotes COVID-19 NCBItxid:2697049
T220 2631-2639 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T164 0-51 Sentence denotes 6 Development of a human monoclonal antibody (mAb)
T165 53-81 Sentence denotes 6.1 Targeting the S protein
T166 83-101 Sentence denotes 6.1.1 Hypothesis:
T167 102-179 Sentence denotes A mAb against the binding domain of the virus can inhibit SARS-CoV2 infection
T168 180-466 Sentence denotes Recently, hybridoma supernatants containing antibody repertoires from immunized transgenic mice that express the human immunoglobulin heavy and light chains and rat origin immunoglobulin constant regions were used to detect antibodies that can cross neutralize SARS-S and SARS-2-S [26].
T169 467-687 Sentence denotes One chimeric 47D11 H2L2 antibody displayed such a cross-neutralizing activity, decreased syncytia formation induced by SARS-S and SARS2-S, and could protect VeroE6 cells against SARS-S and SARS2-S pseudotyped virus [26].
T170 688-820 Sentence denotes It may lie in its similar affinities for interacting with the same domain of the S1 subunit, i.e., S1B, of each SARS-S and SARS-2-S.
T171 822-838 Sentence denotes 6.1.2 Rational:
T172 839-923 Sentence denotes The chimeric 47D11 H2L2 might not be effective in human lung cells as it is in vitro
T173 924-1024 Sentence denotes 47D11 carried a higher affinity for interacting with the S2 subunit of SARS-S than that of SARS-2-S.
T174 1025-1206 Sentence denotes It is important that for both SARS-S and SARS-2-S, the binding of the 47D11 antibody to the target – the S1B domain – does not block the binding of S1B and S2 to ACE2 receptor [26].
T175 1207-1326 Sentence denotes By contrast, neutralizing antibodies that specifically target SARS-S could compete with S1B and S2 for binding to ACE2.
T176 1328-1369 Sentence denotes 6.2 Targeting pro-inflammatory cytokines
T177 1371-1389 Sentence denotes 6.2.1 Hypothesis:
T178 1390-1440 Sentence denotes A mAb against IL6 can attenuate hyper inflammation
T179 1441-1769 Sentence denotes Tocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis.
T180 1770-1851 Sentence denotes It is safe and effective for both adults and children two years of age and older.
T181 1853-1870 Sentence denotes 6.2.2 Rationale:
T182 1871-1950 Sentence denotes Tocilizumab can treat lung injury in patients with critical and severe COVID-19
T183 1951-2098 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 2099-2317 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 2318-2376 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 2377-2456 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.
T187 2457-2563 Sentence denotes There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19.
T188 2564-2779 Sentence denotes Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28].

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T21 895-899 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T22 1893-1897 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T23 2324-2328 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
693 20-25 Species denotes human Tax:9606
696 160-169 Species denotes SARS-CoV2 Tax:2697049
697 170-179 Disease denotes infection MESH:D007239
719 260-275 Species denotes transgenic mice Tax:10090
720 293-298 Species denotes human Tax:9606
721 341-344 Species denotes rat Tax:10116
722 452-458 Species denotes SARS-2 Tax:2697049
718 459-460 Gene denotes S Gene:43740568
726 546-564 Disease denotes decreased syncytia MESH:D002303
717 591-592 Gene denotes S Gene:43740568
723 597-602 Species denotes SARS2 Tax:2697049
716 603-604 Gene denotes S Gene:43740568
727 624-630 CellLine denotes VeroE6 CVCL:0574
724 656-661 Species denotes SARS2 Tax:2697049
715 662-663 Gene denotes S Gene:43740568
714 805-806 Gene denotes S Gene:43740568
725 811-817 Species denotes SARS-2 Tax:2697049
713 818-819 Gene denotes S Gene:43740568
729 889-894 Species denotes human Tax:9606
745 1000-1001 Gene denotes S Gene:43740568
746 1015-1021 Species denotes SARS-2 Tax:2697049
744 1022-1023 Gene denotes S Gene:43740568
743 1060-1061 Gene denotes S Gene:43740568
747 1066-1072 Species denotes SARS-2 Tax:2697049
742 1073-1074 Gene denotes S Gene:43740568
739 1187-1191 Gene denotes ACE2 Gene:59272
741 1274-1275 Gene denotes S Gene:43740568
740 1321-1325 Gene denotes ACE2 Gene:59272
750 1404-1407 Gene denotes IL6 Gene:3569
751 1422-1440 Disease denotes hyper inflammation MESH:D007249
762 1441-1452 Chemical denotes Tocilizumab MESH:C502936
761 1499-1504 Species denotes human Tax:9606
763 1572-1591 Disease denotes autoimmune diseases MESH:D001327
764 1635-1655 Disease denotes rheumatoid arthritis MESH:D001172
765 1657-1677 Disease denotes giant cell arteritis MESH:D013700
766 1679-1722 Disease denotes polyarticular juvenile idiopathic arthritis MESH:D001171
767 1728-1768 Disease denotes systematic juvenile idiopathic arthritis MESH:D001171
760 1815-1823 Species denotes children Tax:9606
773 1871-1882 Chemical denotes Tocilizumab MESH:C502936
774 1893-1904 Disease denotes lung injury MESH:D055370
772 1908-1916 Species denotes patients Tax:9606
775 1942-1950 Disease denotes COVID-19 MESH:C000657245
790 1973-1981 Species denotes patients Tax:9606
797 1987-1995 Disease denotes COVID-19 MESH:C000657245
793 2064-2075 Chemical denotes Tocilizumab MESH:C502936
791 2099-2107 Species denotes Patients Tax:9606
788 2123-2126 Gene denotes IL6 Gene:3569
794 2163-2174 Chemical denotes tocilizumab MESH:C502936
795 2240-2246 Chemical denotes oxygen MESH:D010100
789 2306-2309 Gene denotes CRP Gene:1401
798 2324-2335 Disease denotes lung lesion MESH:D008171
792 2367-2375 Species denotes patients Tax:9606
799 2413-2419 Disease denotes deaths MESH:D003643
796 2434-2445 Chemical denotes tocilizumab MESH:C502936
811 2495-2506 Chemical denotes tocilizumab MESH:C502936
809 2520-2528 Species denotes patients Tax:9606
813 2554-2562 Disease denotes COVID-19 MESH:C000657245
812 2586-2597 Chemical denotes Tocilizumab MESH:C502936
810 2617-2625 Species denotes patients Tax:9606
814 2631-2639 Disease denotes COVID-19 MESH:C000657245
815 2666-2684 Disease denotes hyper inflammation MESH:D007249
808 2708-2711 Gene denotes IL6 Gene:3569

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T2036 72-81 Protein denotes S protein https://www.uniprot.org/uniprot/Q9UIP0|https://www.uniprot.org/uniprot/Q9UIN9|https://www.uniprot.org/uniprot/Q9UIN8|https://www.uniprot.org/uniprot/Q9UIN7|https://www.uniprot.org/uniprot/Q9UIN6|https://www.uniprot.org/uniprot/Q9UBH8|https://www.uniprot.org/uniprot/Q9NRH8|https://www.uniprot.org/uniprot/Q9NRH7|https://www.uniprot.org/uniprot/Q9NRH6|https://www.uniprot.org/uniprot/Q9NRH5|https://www.uniprot.org/uniprot/Q9NRH4|https://www.uniprot.org/uniprot/Q9NPG5|https://www.uniprot.org/uniprot/Q9NPE0|https://www.uniprot.org/uniprot/Q9NP52|https://www.uniprot.org/uniprot/Q95IF9|https://www.uniprot.org/uniprot/Q8N5P3|https://www.uniprot.org/uniprot/Q8IZU6|https://www.uniprot.org/uniprot/Q8IZU5|https://www.uniprot.org/uniprot/Q8IZU4|https://www.uniprot.org/uniprot/Q86Z04|https://www.uniprot.org/uniprot/Q7YR44|https://www.uniprot.org/uniprot/Q7LA71|https://www.uniprot.org/uniprot/Q7LA70|https://www.uniprot.org/uniprot/Q5STD2|https://www.uniprot.org/uniprot/Q5SQ85|https://www.uniprot.org/uniprot/Q1XI16|https://www.uniprot.org/uniprot/Q1XI12|https://www.uniprot.org/uniprot/Q15517|https://www.uniprot.org/uniprot/O43509|https://www.uniprot.org/uniprot/O19084|https://www.uniprot.org/uniprot/B0UYZ7|https://www.uniprot.org/uniprot/B0S7V2|https://www.uniprot.org/uniprot/A5A6L9
T2069 787-790 Protein denotes S1B https://www.uniprot.org/uniprot/P47835
T2070 1130-1133 Protein denotes S1B https://www.uniprot.org/uniprot/P47835
T2071 1173-1176 Protein denotes S1B https://www.uniprot.org/uniprot/P47835
T2072 1295-1298 Protein denotes S1B https://www.uniprot.org/uniprot/P47835
T2073 1404-1407 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T2117 1505-1508 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T2161 2123-2126 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T2205 2306-2309 Protein denotes CRP https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268
T2216 2708-2711 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T2260 2713-2721 Protein denotes ferritin https://www.uniprot.org/uniprot/Q26061

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T22399 0-1 CD denotes 6
T82716 3-14 NN denotes Development
T5151 15-17 IN denotes of
T20950 18-19 DT denotes a
T64967 20-25 JJ denotes human
T94716 26-36 JJ denotes monoclonal
T29466 37-45 NN denotes antibody
T27300 46-47 -LRB- denotes (
T65405 47-50 NN denotes mAb
T53967 50-51 -RRB- denotes )
T20998 53-56 CD denotes 6.1
T79456 58-67 VBG denotes Targeting
T24060 68-71 DT denotes the
T56819 72-73 NN denotes S
T25577 74-81 NN denotes protein
T96682 83-88 CD denotes 6.1.1
T17328 90-100 NN denotes Hypothesis
T61727 100-101 -COLON- denotes :
T32221 102-103 DT denotes A
T25878 104-107 NN denotes mAb
T8625 108-115 IN denotes against
T32030 116-119 DT denotes the
T55531 120-127 NN denotes binding
T9970 128-134 NN denotes domain
T76093 135-137 IN denotes of
T80345 138-141 DT denotes the
T93532 142-147 NN denotes virus
T16199 148-151 MD denotes can
T28417 152-159 VB denotes inhibit
T48409 160-169 NN denotes SARS-CoV2
T36310 170-179 NN denotes infection
T27915 180-188 RB denotes Recently
T56144 188-189 -COMMA- denotes ,
T55915 190-199 NN denotes hybridoma
T72012 200-212 NNS denotes supernatants
T47163 213-223 VBG denotes containing
T24138 224-232 NN denotes antibody
T98139 233-244 NNS denotes repertoires
T66535 245-249 IN denotes from
T86473 250-259 VBN denotes immunized
T66245 260-270 JJ denotes transgenic
T17100 271-275 NNS denotes mice
T85324 276-280 WDT denotes that
T55347 281-288 VBP denotes express
T14738 289-292 DT denotes the
T52540 293-298 JJ denotes human
T35586 299-313 NN denotes immunoglobulin
T72563 314-319 JJ denotes heavy
T65069 320-323 CC denotes and
T5967 324-329 JJ denotes light
T98095 330-336 NNS denotes chains
T78221 337-340 CC denotes and
T28318 341-344 NN denotes rat
T19776 345-351 NN denotes origin
T32531 352-366 NN denotes immunoglobulin
T16968 367-375 NN denotes constant
T56920 376-383 NNS denotes regions
T36716 384-388 VBD denotes were
T74827 389-393 VBN denotes used
T21382 394-396 TO denotes to
T11788 397-403 VB denotes detect
T40665 404-414 NNS denotes antibodies
T56747 415-419 WDT denotes that
T54239 420-423 MD denotes can
T71867 424-429 VB denotes cross
T35671 430-440 VB denotes neutralize
T77445 441-447 NN denotes SARS-S
T34654 448-451 CC denotes and
T83470 452-460 NN denotes SARS-2-S
T76245 461-462 -LRB- denotes [
T33581 462-464 CD denotes 26
T80577 464-465 -RRB- denotes ]
T78516 467-470 CD denotes One
T34464 471-479 JJ denotes chimeric
T13041 480-485 NN denotes 47D11
T83927 486-490 NN denotes H2L2
T57345 491-499 NN denotes antibody
T44833 500-509 VBD denotes displayed
T94688 510-514 PDT denotes such
T52983 515-516 DT denotes a
T30646 517-535 JJ denotes cross-neutralizing
T37245 536-544 NN denotes activity
T11300 544-545 -COMMA- denotes ,
T30814 546-555 VBD denotes decreased
T23282 556-564 NN denotes syncytia
T72581 565-574 NN denotes formation
T71888 575-582 VBN denotes induced
T44111 583-585 IN denotes by
T7869 586-592 NN denotes SARS-S
T80909 593-596 CC denotes and
T58127 597-604 NN denotes SARS2-S
T9479 604-605 -COMMA- denotes ,
T96346 606-609 CC denotes and
T43362 610-615 MD denotes could
T48435 616-623 VB denotes protect
T44775 624-630 NN denotes VeroE6
T25625 631-636 NNS denotes cells
T19104 637-644 IN denotes against
T51640 645-651 NN denotes SARS-S
T22676 652-655 CC denotes and
T37470 656-663 NN denotes SARS2-S
T64695 664-675 VBD denotes pseudotyped
T26978 676-681 NN denotes virus
T79137 682-683 -LRB- denotes [
T95558 683-685 CD denotes 26
T95168 685-686 -RRB- denotes ]
T45371 688-690 PRP denotes It
T75403 691-694 MD denotes may
T86603 695-698 VB denotes lie
T91829 699-701 IN denotes in
T48175 702-705 PRP-DOLLAR- denotes its
T69338 706-713 JJ denotes similar
T68140 714-724 NNS denotes affinities
T76951 725-728 IN denotes for
T38362 729-740 VBG denotes interacting
T39715 741-745 IN denotes with
T48378 746-749 DT denotes the
T63623 750-754 JJ denotes same
T2491 755-761 NN denotes domain
T57621 762-764 IN denotes of
T77993 765-768 DT denotes the
T52886 769-771 NN denotes S1
T27554 772-779 NN denotes subunit
T41139 779-780 -COMMA- denotes ,
T99819 781-785 FW denotes i.e.
T40027 785-786 -COMMA- denotes ,
T73637 787-790 NN denotes S1B
T71055 790-791 -COMMA- denotes ,
T88888 792-794 IN denotes of
T40209 795-799 DT denotes each
T2572 800-806 NN denotes SARS-S
T97128 807-810 CC denotes and
T91104 811-819 NN denotes SARS-2-S
T63608 822-827 CD denotes 6.1.2
T11815 829-837 NNP denotes Rational
T73902 837-838 -COLON- denotes :
T21134 839-842 DT denotes The
T30867 843-851 JJ denotes chimeric
T42126 852-857 NN denotes 47D11
T93924 858-862 NN denotes H2L2
T85248 863-868 MD denotes might
T92338 869-872 RB denotes not
T49873 873-875 VB denotes be
T69919 876-885 JJ denotes effective
T60557 886-888 IN denotes in
T77242 889-894 JJ denotes human
T86725 895-899 NN denotes lung
T18333 900-905 NNS denotes cells
T22947 906-908 IN denotes as
T22184 909-911 PRP denotes it
T1922 912-914 VBZ denotes is
T72123 915-917 FW denotes in
T38972 918-923 FW denotes vitro
T22398 924-929 NN denotes 47D11
T15962 930-937 VBD denotes carried
T83196 938-939 DT denotes a
T61532 940-946 JJR denotes higher
T47874 947-955 NN denotes affinity
T77580 956-959 IN denotes for
T95631 960-971 VBG denotes interacting
T94847 972-976 IN denotes with
T20163 977-980 DT denotes the
T18520 981-983 NN denotes S2
T89003 984-991 NN denotes subunit
T41606 992-994 IN denotes of
T4784 995-1001 NN denotes SARS-S
T32288 1002-1006 IN denotes than
T68894 1007-1011 DT denotes that
T97000 1012-1014 IN denotes of
T32517 1015-1024 NN denotes SARS-2-S.
T24633 1025-1027 PRP denotes It
T45480 1028-1030 VBZ denotes is
T10954 1031-1040 JJ denotes important
T96386 1041-1045 IN denotes that
T80967 1046-1049 IN denotes for
T24571 1050-1054 DT denotes both
T18211 1055-1061 NN denotes SARS-S
T39196 1062-1065 CC denotes and
T83081 1066-1074 NN denotes SARS-2-S
T70298 1074-1075 -COMMA- denotes ,
T91479 1076-1079 DT denotes the
T56884 1080-1087 NN denotes binding
T11559 1088-1090 IN denotes of
T2922 1091-1094 DT denotes the
T11592 1095-1100 NN denotes 47D11
T36887 1101-1109 NN denotes antibody
T46706 1110-1112 TO denotes to
T40788 1113-1116 DT denotes the
T37833 1117-1123 NN denotes target
T37378 1124-1125 VBZ denotes –
T15003 1126-1129 DT denotes the
T4372 1130-1133 NN denotes S1B
T31100 1134-1140 NN denotes domain
T82065 1141-1142 NN denotes –
T43926 1143-1147 VBZ denotes does
T69422 1148-1151 RB denotes not
T3419 1152-1157 VB denotes block
T21955 1158-1161 DT denotes the
T12942 1162-1169 NN denotes binding
T83444 1170-1172 IN denotes of
T49120 1173-1176 NN denotes S1B
T55070 1177-1180 CC denotes and
T98634 1181-1183 NN denotes S2
T48321 1184-1186 TO denotes to
T80580 1187-1191 NN denotes ACE2
T18877 1192-1200 NN denotes receptor
T18503 1201-1202 -LRB- denotes [
T33177 1202-1204 CD denotes 26
T92006 1204-1205 -RRB- denotes ]
T53652 1207-1209 IN denotes By
T58622 1210-1218 NN denotes contrast
T35381 1218-1219 -COMMA- denotes ,
T41843 1220-1232 VBG denotes neutralizing
T81589 1233-1243 NNS denotes antibodies
T68196 1244-1248 WDT denotes that
T30816 1249-1261 RB denotes specifically
T53446 1262-1268 NN denotes target
T89813 1269-1275 NN denotes SARS-S
T95236 1276-1281 MD denotes could
T7888 1282-1289 VB denotes compete
T34125 1290-1294 IN denotes with
T82101 1295-1298 NN denotes S1B
T1902 1299-1302 CC denotes and
T24277 1303-1305 NN denotes S2
T37015 1306-1309 IN denotes for
T86465 1310-1317 VBG denotes binding
T1893 1318-1320 TO denotes to
T91196 1321-1325 NN denotes ACE2
T54390 1328-1331 CD denotes 6.2
T7377 1333-1342 VBG denotes Targeting
T2754 1343-1359 JJ denotes pro-inflammatory
T79617 1360-1369 NNS denotes cytokines
T42975 1371-1376 CD denotes 6.2.1
T96891 1378-1388 NN denotes Hypothesis
T41163 1388-1389 -COLON- denotes :
T35174 1390-1391 DT denotes A
T74401 1392-1395 NN denotes mAb
T75556 1396-1403 IN denotes against
T83617 1404-1407 NN denotes IL6
T67953 1408-1411 MD denotes can
T68840 1412-1421 VB denotes attenuate
T2426 1422-1427 NN denotes hyper
T92661 1428-1440 NN denotes inflammation
T86439 1441-1452 NNP denotes Tocilizumab
T21494 1452-1453 -COMMA- denotes ,
T50157 1454-1458 RB denotes also
T26283 1459-1464 VBN denotes known
T43571 1465-1467 IN denotes as
T44785 1468-1477 NN denotes atlizumab
T96810 1477-1478 -COMMA- denotes ,
T58761 1479-1481 VBZ denotes is
T56416 1482-1483 DT denotes a
T79548 1484-1493 JJ denotes humanized
T29074 1494-1504 JJ denotes anti-human
T88685 1505-1508 NN denotes IL6
T26777 1509-1517 NN denotes receptor
T24185 1518-1526 NN denotes antibody
T17221 1527-1535 VBN denotes approved
T32471 1536-1538 IN denotes by
T53882 1539-1542 NNP denotes FDA
T24580 1543-1546 IN denotes for
T33924 1547-1554 JJ denotes several
T90119 1555-1567 JJ denotes inflammatory
T59846 1568-1571 CC denotes and
T31666 1572-1582 JJ denotes autoimmune
T46803 1583-1591 NNS denotes diseases
T80969 1592-1598 JJ denotes severe
T13017 1598-1599 -COMMA- denotes ,
T79015 1600-1604 JJ denotes such
T43255 1605-1607 IN denotes as
T47553 1608-1616 NN denotes cytokine
T34694 1617-1624 NN denotes release
T36705 1625-1633 NN denotes syndrome
T68837 1633-1634 -COMMA- denotes ,
T30269 1635-1645 JJ denotes rheumatoid
T54700 1646-1655 NN denotes arthritis
T81658 1655-1656 -COMMA- denotes ,
T84650 1657-1662 JJ denotes giant
T11095 1663-1667 NN denotes cell
T15987 1668-1677 NN denotes arteritis
T88887 1677-1678 -COMMA- denotes ,
T31599 1679-1692 JJ denotes polyarticular
T93322 1693-1701 JJ denotes juvenile
T49595 1702-1712 JJ denotes idiopathic
T62141 1713-1722 NN denotes arthritis
T76737 1722-1723 -COMMA- denotes ,
T30470 1724-1727 CC denotes and
T13999 1728-1738 JJ denotes systematic
T88238 1739-1747 JJ denotes juvenile
T89892 1748-1758 JJ denotes idiopathic
T97598 1759-1768 NN denotes arthritis
T25454 1770-1772 PRP denotes It
T28665 1773-1775 VBZ denotes is
T15312 1776-1780 JJ denotes safe
T18121 1781-1784 CC denotes and
T2467 1785-1794 JJ denotes effective
T39207 1795-1798 IN denotes for
T89869 1799-1803 DT denotes both
T32842 1804-1810 NNS denotes adults
T38357 1811-1814 CC denotes and
T13891 1815-1823 NNS denotes children
T61388 1824-1827 CD denotes two
T66576 1828-1833 NNS denotes years
T46590 1834-1836 IN denotes of
T15404 1837-1840 NN denotes age
T19164 1841-1844 CC denotes and
T99851 1845-1850 JJR denotes older
T41884 1853-1858 CD denotes 6.2.2
T3706 1860-1869 NNP denotes Rationale
T87509 1869-1870 -COLON- denotes :
T72411 1871-1882 NNP denotes Tocilizumab
T46139 1883-1886 MD denotes can
T80638 1887-1892 VB denotes treat
T14365 1893-1897 NN denotes lung
T88114 1898-1904 NN denotes injury
T76208 1905-1907 IN denotes in
T24628 1908-1916 NNS denotes patients
T15777 1917-1921 IN denotes with
T58130 1922-1930 JJ denotes critical
T31522 1931-1934 CC denotes and
T55163 1935-1941 JJ denotes severe
T92225 1942-1950 NN denotes COVID-19
T21073 1951-1953 IN denotes In
T65150 1954-1957 DT denotes the
T61991 1958-1963 NN denotes study
T18474 1964-1965 -LRB- denotes [
T8341 1965-1967 CD denotes 27
T6430 1967-1968 -RRB- denotes ]
T29393 1968-1969 -COMMA- denotes ,
T77821 1970-1972 CD denotes 21
T79215 1973-1981 NNS denotes patients
T5404 1982-1986 IN denotes with
T75582 1987-1995 NN denotes COVID-19
T89299 1996-2001 WP-DOLLAR- denotes whose
T66055 2002-2011 NN denotes condition
T80340 2012-2015 VBD denotes was
T3490 2016-2022 JJ denotes severe
T44653 2023-2025 CC denotes or
T55941 2026-2034 JJ denotes critical
T85453 2035-2043 VBD denotes received
T98598 2044-2047 CD denotes one
T96881 2048-2050 CC denotes or
T24534 2051-2054 CD denotes two
T70238 2055-2060 NNS denotes doses
T20616 2061-2063 IN denotes of
T68912 2064-2075 NNP denotes Tocilizumab
T98192 2076-2080 CC denotes plus
T20706 2081-2089 JJ denotes standard
T58005 2090-2097 NN denotes therapy
T96625 2099-2107 NNS denotes Patients
T75572 2108-2111 WP denotes who
T31917 2112-2115 VBD denotes had
T15301 2116-2117 DT denotes a
T24848 2118-2122 JJ denotes mean
T84688 2123-2126 NN denotes IL6
T96963 2127-2132 NN denotes level
T6930 2133-2135 IN denotes of
T90933 2136-2140 JJR denotes more
T81944 2141-2145 IN denotes than
T75581 2146-2155 NN denotes 100 pg/ml
T64021 2156-2162 IN denotes before
T9387 2163-2174 NN denotes tocilizumab
T84664 2175-2184 NN denotes treatment
T18203 2185-2191 VBD denotes showed
T60803 2192-2203 NN denotes improvement
T44490 2204-2206 IN denotes in
T81402 2207-2215 JJ denotes clinical
T14228 2216-2224 NNS denotes symptoms
T94537 2225-2228 CC denotes and
T83697 2229-2239 JJ denotes peripheral
T13978 2240-2246 NN denotes oxygen
T35808 2247-2257 NN denotes saturation
T34900 2258-2261 CC denotes and
T75964 2262-2275 NN denotes normalization
T84268 2276-2279 IN denotes for
T65028 2280-2290 NN denotes lymphocyte
T34390 2291-2301 NN denotes proportion
T96610 2302-2305 CC denotes and
T30755 2306-2309 NN denotes CRP
T63070 2310-2316 NNS denotes levels
T31791 2318-2322 RB denotes Also
T31152 2322-2323 -COMMA- denotes ,
T79595 2324-2328 NN denotes lung
T51431 2329-2335 NN denotes lesion
T10130 2336-2343 NN denotes opacity
T31388 2344-2347 VBD denotes was
T1824 2348-2356 VBN denotes absorbed
T60055 2357-2359 IN denotes in
T38598 2360-2362 CD denotes 90
T67288 2362-2363 NN denotes %
T48683 2364-2366 IN denotes of
T41529 2367-2375 NNS denotes patients
T69670 2377-2384 CC denotes Neither
T9277 2385-2392 JJ denotes serious
T15021 2393-2400 JJ denotes adverse
T23626 2401-2408 NNS denotes effects
T98539 2409-2412 CC denotes nor
T65699 2413-2419 NNS denotes deaths
T50204 2420-2428 VBD denotes occurred
T20973 2429-2433 IN denotes with
T14012 2434-2445 NN denotes tocilizumab
T66286 2446-2455 NN denotes treatment
T24269 2457-2462 EX denotes There
T26765 2463-2466 VBP denotes are
T84711 2467-2474 VBG denotes ongoing
T74304 2475-2483 JJ denotes clinical
T68003 2484-2490 NNS denotes trials
T5000 2491-2494 IN denotes for
T64198 2495-2506 NN denotes tocilizumab
T83078 2507-2516 NN denotes treatment
T11331 2517-2519 IN denotes in
T42834 2520-2528 NNS denotes patients
T27205 2529-2533 IN denotes with
T23786 2534-2542 JJ denotes moderate
T45333 2543-2546 CC denotes and
T9137 2547-2553 JJ denotes severe
T27842 2554-2562 NN denotes COVID-19
T92236 2564-2573 RB denotes Currently
T32112 2573-2574 -COMMA- denotes ,
T54987 2575-2578 DT denotes the
T85855 2579-2582 NN denotes use
T69355 2583-2585 IN denotes of
T40115 2586-2597 NNP denotes Tocilizumab
T10850 2598-2600 VBZ denotes is
T78367 2601-2612 VBN denotes recommended
T33042 2613-2616 IN denotes for
T36466 2617-2625 NNS denotes patients
T61983 2626-2630 IN denotes with
T2749 2631-2639 NN denotes COVID-19
T17580 2640-2643 WP denotes who
T69055 2644-2648 VBP denotes have
T71996 2649-2656 VBG denotes warning
T59356 2657-2662 NNS denotes signs
T65527 2663-2665 IN denotes of
T99769 2666-2671 NN denotes hyper
T44301 2672-2684 NN denotes inflammation
T54453 2684-2685 -COMMA- denotes ,
T58078 2686-2688 IN denotes as
T75237 2689-2692 MD denotes can
T7496 2693-2695 VB denotes be
T53845 2696-2704 VBN denotes measured
T78207 2705-2707 IN denotes by
T88455 2708-2711 NN denotes IL6
T77671 2711-2712 -COMMA- denotes ,
T67481 2713-2721 NN denotes ferritin
T99390 2721-2722 -COMMA- denotes ,
T23484 2723-2731 NN denotes platelet
T65701 2732-2738 NNS denotes counts
T30323 2738-2739 -COMMA- denotes ,
T72053 2740-2752 JJ denotes inflammatory
T81575 2753-2760 NNS denotes markers
T96428 2760-2761 -COMMA- denotes ,
T36542 2762-2765 CC denotes and
T88469 2766-2767 NN denotes H
T51141 2768-2773 NN denotes score
T97739 2774-2775 -LRB- denotes [
T29313 2775-2777 CD denotes 28
T54016 2777-2778 -RRB- denotes ]
R44206 T82716 T22399 arg1Of Development,6
R91476 T82716 T5151 arg1Of Development,of
R14488 T29466 T5151 arg2Of antibody,of
R53814 T29466 T20950 arg1Of antibody,a
R52641 T29466 T64967 arg1Of antibody,human
R46895 T29466 T94716 arg1Of antibody,monoclonal
R5884 T29466 T27300 arg1Of antibody,(
R3792 T65405 T27300 arg2Of mAb,(
R42067 T53967 T27300 arg3Of ),(
R5031 T20998 T79456 arg1Of 6.1,Targeting
R28532 T25577 T79456 arg2Of protein,Targeting
R81579 T25577 T24060 arg1Of protein,the
R73916 T25577 T56819 arg1Of protein,S
R32719 T17328 T96682 arg1Of Hypothesis,6.1.1
R34441 T17328 T61727 arg1Of Hypothesis,:
R7667 T25878 T32221 arg1Of mAb,A
R91773 T25878 T8625 arg1Of mAb,against
R23833 T9970 T8625 arg2Of domain,against
R92213 T9970 T32030 arg1Of domain,the
R57443 T9970 T55531 arg1Of domain,binding
R31979 T9970 T76093 arg1Of domain,of
R76879 T93532 T76093 arg2Of virus,of
R54102 T93532 T80345 arg1Of virus,the
R20587 T25878 T16199 arg1Of mAb,can
R25119 T28417 T16199 arg2Of inhibit,can
R58250 T17328 T16199 modOf Hypothesis,can
R15396 T25878 T28417 arg1Of mAb,inhibit
R9435 T36310 T28417 arg2Of infection,inhibit
R6804 T36310 T48409 arg1Of infection,SARS-CoV2
R33983 T74827 T27915 arg1Of used,Recently
R66835 T74827 T56144 arg1Of used,","
R79461 T72012 T55915 arg1Of supernatants,hybridoma
R93366 T72012 T47163 arg1Of supernatants,containing
R25704 T98139 T47163 arg2Of repertoires,containing
R90990 T98139 T24138 arg1Of repertoires,antibody
R94676 T98139 T66535 arg1Of repertoires,from
R63011 T17100 T66535 arg2Of mice,from
R10738 T17100 T86473 arg2Of mice,immunized
R74916 T17100 T66245 arg1Of mice,transgenic
R8726 T98139 T85324 arg1Of repertoires,that
R22914 T98139 T55347 arg1Of repertoires,express
R91506 T78221 T55347 arg2Of and,express
R63116 T78221 T14738 arg1Of and,the
R50898 T98095 T52540 arg1Of chains,human
R6996 T98095 T35586 arg1Of chains,immunoglobulin
R54748 T98095 T72563 arg1Of chains,heavy
R94533 T72563 T65069 arg1Of heavy,and
R51991 T5967 T65069 arg2Of light,and
R10518 T98095 T5967 arg1Of chains,light
R78842 T98095 T78221 arg1Of chains,and
R33937 T56920 T78221 arg2Of regions,and
R92294 T56920 T28318 arg1Of regions,rat
R87268 T56920 T19776 arg1Of regions,origin
R7737 T56920 T32531 arg1Of regions,immunoglobulin
R98342 T56920 T16968 arg1Of regions,constant
R65646 T72012 T36716 arg1Of supernatants,were
R67139 T74827 T36716 arg2Of used,were
R67837 T72012 T74827 arg2Of supernatants,used
R69341 T11788 T74827 arg3Of detect,used
R12801 T11788 T21382 arg1Of detect,to
R52958 T40665 T11788 arg2Of antibodies,detect
R77806 T40665 T56747 arg1Of antibodies,that
R37476 T40665 T54239 arg1Of antibodies,can
R87983 T35671 T54239 arg2Of neutralize,can
R24714 T40665 T71867 arg1Of antibodies,cross
R29418 T35671 T71867 arg2Of neutralize,cross
R8917 T40665 T35671 arg1Of antibodies,neutralize
R70086 T34654 T35671 arg2Of and,neutralize
R88560 T77445 T34654 arg1Of SARS-S,and
R74668 T83470 T34654 arg2Of SARS-2-S,and
R89642 T35671 T76245 arg1Of neutralize,[
R10178 T33581 T76245 arg2Of 26,[
R12224 T80577 T76245 arg3Of ],[
R55425 T57345 T78516 arg1Of antibody,One
R85824 T57345 T34464 arg1Of antibody,chimeric
R91166 T57345 T13041 arg1Of antibody,47D11
R74139 T57345 T83927 arg1Of antibody,H2L2
R37082 T57345 T44833 arg1Of antibody,displayed
R42165 T37245 T44833 arg2Of activity,displayed
R8404 T37245 T94688 arg1Of activity,such
R58851 T37245 T52983 arg1Of activity,a
R6725 T37245 T30646 arg1Of activity,cross-neutralizing
R48595 T44833 T11300 arg1Of displayed,","
R75181 T30814 T11300 arg2Of decreased,","
R32317 T57345 T30814 arg1Of antibody,decreased
R66912 T72581 T30814 arg2Of formation,decreased
R2953 T72581 T23282 arg1Of formation,syncytia
R53752 T80909 T71888 arg1Of and,induced
R39715 T72581 T71888 arg2Of formation,induced
R78219 T80909 T44111 arg2Of and,by
R96452 T7869 T80909 arg1Of SARS-S,and
R84017 T58127 T80909 arg2Of SARS2-S,and
R48482 T96346 T9479 arg1Of and,","
R37253 T11300 T96346 arg1Of ",",and
R96321 T48435 T96346 arg2Of protect,and
R73215 T57345 T43362 arg1Of antibody,could
R33694 T48435 T43362 arg2Of protect,could
R79302 T57345 T48435 arg1Of antibody,protect
R44320 T25625 T48435 arg2Of cells,protect
R54339 T25625 T44775 arg1Of cells,VeroE6
R74716 T48435 T19104 arg1Of protect,against
R67161 T22676 T19104 arg2Of and,against
R67960 T51640 T22676 arg1Of SARS-S,and
R58716 T37470 T22676 arg2Of SARS2-S,and
R42573 T22676 T64695 arg2Of and,pseudotyped
R23893 T26978 T64695 arg3Of virus,pseudotyped
R62516 T26978 T79137 arg1Of virus,[
R68991 T95558 T79137 arg2Of 26,[
R21425 T95168 T79137 arg3Of ],[
R57799 T45371 T75403 arg1Of It,may
R22045 T86603 T75403 arg2Of lie,may
R27208 T45371 T86603 arg1Of It,lie
R30853 T86603 T91829 arg1Of lie,in
R8563 T68140 T91829 arg2Of affinities,in
R84051 T68140 T48175 arg1Of affinities,its
R54251 T68140 T69338 arg1Of affinities,similar
R17475 T68140 T76951 arg1Of affinities,for
R24043 T38362 T76951 arg2Of interacting,for
R92728 T38362 T39715 arg1Of interacting,with
R17122 T2491 T39715 arg2Of domain,with
R47571 T2491 T48378 arg1Of domain,the
R29816 T2491 T63623 arg1Of domain,same
R3874 T2491 T57621 arg1Of domain,of
R51485 T27554 T57621 arg2Of subunit,of
R73905 T27554 T77993 arg1Of subunit,the
R30509 T27554 T52886 arg1Of subunit,S1
R24972 T68140 T41139 arg1Of affinities,","
R48015 T68140 T99819 arg1Of affinities,i.e.
R85163 T73637 T99819 arg2Of S1B,i.e.
R34990 T99819 T40027 arg1Of i.e.,","
R84082 T68140 T71055 arg1Of affinities,","
R73965 T68140 T88888 arg1Of affinities,of
R44270 T97128 T88888 arg2Of and,of
R2062 T97128 T40209 arg1Of and,each
R35318 T2572 T97128 arg1Of SARS-S,and
R89938 T91104 T97128 arg2Of SARS-2-S,and
R6870 T11815 T63608 arg1Of Rational,6.1.2
R99987 T11815 T73902 arg1Of Rational,:
R39394 T93924 T21134 arg1Of H2L2,The
R27252 T93924 T30867 arg1Of H2L2,chimeric
R91021 T93924 T42126 arg1Of H2L2,47D11
R85301 T93924 T85248 arg1Of H2L2,might
R68664 T49873 T85248 arg2Of be,might
R85602 T49873 T92338 arg1Of be,not
R73472 T93924 T49873 arg1Of H2L2,be
R56902 T69919 T49873 arg2Of effective,be
R30813 T93924 T69919 arg1Of H2L2,effective
R6463 T49873 T60557 arg1Of be,in
R98023 T18333 T60557 arg2Of cells,in
R22781 T18333 T77242 arg1Of cells,human
R95568 T18333 T86725 arg1Of cells,lung
R57926 T49873 T22947 arg1Of be,as
R49211 T1922 T22947 arg2Of is,as
R60499 T22184 T1922 arg1Of it,is
R70730 T38972 T72123 arg1Of vitro,in
R68061 T1922 T38972 arg1Of is,vitro
R37108 T22398 T15962 arg1Of 47D11,carried
R43602 T47874 T15962 arg2Of affinity,carried
R3397 T47874 T83196 arg1Of affinity,a
R69683 T47874 T61532 arg1Of affinity,higher
R78190 T47874 T77580 arg1Of affinity,for
R68969 T95631 T77580 arg2Of interacting,for
R15040 T95631 T94847 arg1Of interacting,with
R25517 T89003 T94847 arg2Of subunit,with
R53417 T89003 T20163 arg1Of subunit,the
R3997 T89003 T18520 arg1Of subunit,S2
R34556 T89003 T41606 arg1Of subunit,of
R37706 T4784 T41606 arg2Of SARS-S,of
R45826 T47874 T32288 arg1Of affinity,than
R81151 T68894 T32288 arg2Of that,than
R10947 T68894 T97000 arg1Of that,of
R87567 T32517 T97000 arg2Of SARS-2-S.,of
R92430 T24633 T45480 arg1Of It,is
R27880 T10954 T45480 arg2Of important,is
R16446 T47874 T45480 modOf affinity,is
R5059 T24633 T10954 arg1Of It,important
R77514 T47874 T96386 arg1Of affinity,that
R45591 T37378 T96386 arg2Of –,that
R6871 T96386 T80967 arg1Of that,for
R86711 T39196 T80967 arg2Of and,for
R85187 T39196 T24571 arg1Of and,both
R57766 T18211 T39196 arg1Of SARS-S,and
R60594 T83081 T39196 arg2Of SARS-2-S,and
R15467 T37378 T70298 arg1Of –,","
R5494 T56884 T91479 arg1Of binding,the
R79151 T56884 T11559 arg1Of binding,of
R6992 T36887 T11559 arg2Of antibody,of
R62361 T36887 T2922 arg1Of antibody,the
R48343 T36887 T11592 arg1Of antibody,47D11
R35747 T56884 T46706 arg1Of binding,to
R10371 T37833 T46706 arg2Of target,to
R36916 T37833 T40788 arg1Of target,the
R17566 T56884 T37378 arg1Of binding,–
R23617 T3419 T37378 arg2Of block,–
R26619 T82065 T15003 arg1Of –,the
R64854 T82065 T4372 arg1Of –,S1B
R97129 T82065 T31100 arg1Of –,domain
R47400 T82065 T43926 arg1Of –,does
R34720 T3419 T43926 arg2Of block,does
R55812 T3419 T69422 arg1Of block,not
R51826 T82065 T3419 arg1Of –,block
R99609 T12942 T3419 arg2Of binding,block
R35148 T12942 T21955 arg1Of binding,the
R30150 T12942 T83444 arg1Of binding,of
R36055 T55070 T83444 arg2Of and,of
R9737 T49120 T55070 arg1Of S1B,and
R3528 T98634 T55070 arg2Of S2,and
R55511 T12942 T48321 arg1Of binding,to
R91010 T18877 T48321 arg2Of receptor,to
R37042 T18877 T80580 arg1Of receptor,ACE2
R82088 T18877 T18503 arg1Of receptor,[
R55576 T33177 T18503 arg2Of 26,[
R41077 T92006 T18503 arg3Of ],[
R68866 T41843 T53652 arg1Of neutralizing,By
R80894 T58622 T53652 arg2Of contrast,By
R42535 T41843 T35381 arg1Of neutralizing,","
R99048 T81589 T41843 arg1Of antibodies,neutralizing
R45757 T81589 T68196 arg1Of antibodies,that
R2391 T7888 T30816 arg1Of compete,specifically
R14961 T89813 T53446 arg1Of SARS-S,target
R96775 T89813 T95236 arg1Of SARS-S,could
R6780 T7888 T95236 arg2Of compete,could
R40504 T89813 T7888 arg1Of SARS-S,compete
R84230 T81589 T7888 arg2Of antibodies,compete
R48027 T7888 T34125 arg1Of compete,with
R59163 T1902 T34125 arg2Of and,with
R39175 T82101 T1902 arg1Of S1B,and
R95020 T24277 T1902 arg2Of S2,and
R6420 T1902 T37015 arg1Of and,for
R67300 T86465 T37015 arg2Of binding,for
R53767 T86465 T1893 arg1Of binding,to
R3636 T91196 T1893 arg2Of ACE2,to
R75716 T54390 T7377 arg1Of 6.2,Targeting
R93465 T79617 T7377 arg2Of cytokines,Targeting
R69719 T79617 T2754 arg1Of cytokines,pro-inflammatory
R92270 T96891 T42975 arg1Of Hypothesis,6.2.1
R64820 T96891 T41163 arg1Of Hypothesis,:
R32577 T74401 T41163 arg2Of mAb,:
R79527 T74401 T35174 arg1Of mAb,A
R58839 T74401 T75556 arg1Of mAb,against
R72696 T83617 T75556 arg2Of IL6,against
R84073 T96891 T67953 arg1Of Hypothesis,can
R74784 T68840 T67953 arg2Of attenuate,can
R14765 T96891 T68840 arg1Of Hypothesis,attenuate
R94556 T92661 T68840 arg2Of inflammation,attenuate
R98822 T92661 T2426 arg1Of inflammation,hyper
R83125 T86439 T21494 arg1Of Tocilizumab,","
R13146 T26283 T50157 arg1Of known,also
R82868 T86439 T26283 arg2Of Tocilizumab,known
R76811 T26283 T43571 arg1Of known,as
R6462 T44785 T43571 arg2Of atlizumab,as
R65301 T58761 T96810 arg1Of is,","
R91756 T86439 T58761 arg1Of Tocilizumab,is
R48338 T24185 T58761 arg2Of antibody,is
R19276 T24185 T56416 arg1Of antibody,a
R24087 T24185 T79548 arg1Of antibody,humanized
R65895 T24185 T29074 arg1Of antibody,anti-human
R2263 T24185 T88685 arg1Of antibody,IL6
R21524 T24185 T26777 arg1Of antibody,receptor
R18021 T53882 T17221 arg1Of FDA,approved
R77534 T24185 T17221 arg2Of antibody,approved
R58214 T53882 T32471 arg2Of FDA,by
R27887 T17221 T24580 arg1Of approved,for
R20734 T80969 T24580 arg2Of severe,for
R13465 T46803 T33924 arg1Of diseases,several
R86212 T46803 T90119 arg1Of diseases,inflammatory
R60939 T90119 T59846 arg1Of inflammatory,and
R4444 T31666 T59846 arg2Of autoimmune,and
R87485 T46803 T31666 arg1Of diseases,autoimmune
R90538 T46803 T80969 arg1Of diseases,severe
R97819 T17221 T13017 arg1Of approved,","
R24341 T43255 T79015 arg1Of as,such
R92610 T24185 T43255 arg1Of antibody,as
R33248 T30470 T43255 arg2Of and,as
R45357 T36705 T47553 arg1Of syndrome,cytokine
R21959 T36705 T34694 arg1Of syndrome,release
R41949 T36705 T68837 arg1Of syndrome,","
R19260 T54700 T68837 arg2Of arthritis,","
R59437 T54700 T30269 arg1Of arthritis,rheumatoid
R79844 T68837 T81658 arg1Of ",",","
R96846 T15987 T81658 arg2Of arteritis,","
R42046 T15987 T84650 arg1Of arteritis,giant
R12475 T15987 T11095 arg1Of arteritis,cell
R20864 T81658 T88887 arg1Of ",",","
R12170 T62141 T88887 arg2Of arthritis,","
R2759 T62141 T31599 arg1Of arthritis,polyarticular
R56313 T62141 T93322 arg1Of arthritis,juvenile
R57671 T62141 T49595 arg1Of arthritis,idiopathic
R19638 T30470 T76737 arg1Of and,","
R50655 T88887 T30470 arg1Of ",",and
R47508 T97598 T30470 arg2Of arthritis,and
R2665 T97598 T13999 arg1Of arthritis,systematic
R42821 T97598 T88238 arg1Of arthritis,juvenile
R23852 T97598 T89892 arg1Of arthritis,idiopathic
R65763 T25454 T28665 arg1Of It,is
R63345 T18121 T28665 arg2Of and,is
R33385 T25454 T15312 arg1Of It,safe
R71645 T15312 T18121 arg1Of safe,and
R79824 T2467 T18121 arg2Of effective,and
R87665 T25454 T2467 arg1Of It,effective
R86934 T18121 T39207 arg1Of and,for
R81304 T38357 T39207 arg2Of and,for
R77360 T38357 T89869 arg1Of and,both
R78333 T32842 T38357 arg1Of adults,and
R34196 T13891 T38357 arg2Of children,and
R37501 T66576 T61388 arg1Of years,two
R85448 T38357 T66576 arg1Of and,years
R80686 T66576 T46590 arg1Of years,of
R92175 T15404 T46590 arg2Of age,of
R77190 T66576 T19164 arg1Of years,and
R33791 T99851 T19164 arg2Of older,and
R24950 T38357 T99851 arg1Of and,older
R9002 T3706 T41884 arg1Of Rationale,6.2.2
R84332 T3706 T87509 arg1Of Rationale,:
R86004 T72411 T46139 arg1Of Tocilizumab,can
R37530 T80638 T46139 arg2Of treat,can
R92198 T72411 T80638 arg1Of Tocilizumab,treat
R29604 T88114 T80638 arg2Of injury,treat
R90482 T88114 T14365 arg1Of injury,lung
R82985 T80638 T76208 arg1Of treat,in
R69456 T24628 T76208 arg2Of patients,in
R21368 T24628 T15777 arg1Of patients,with
R79687 T92225 T15777 arg2Of COVID-19,with
R76769 T92225 T58130 arg1Of COVID-19,critical
R76550 T58130 T31522 arg1Of critical,and
R20598 T55163 T31522 arg2Of severe,and
R4477 T92225 T55163 arg1Of COVID-19,severe
R75326 T85453 T21073 arg1Of received,In
R27739 T61991 T21073 arg2Of study,In
R82994 T61991 T65150 arg1Of study,the
R48681 T61991 T18474 arg1Of study,[
R80450 T8341 T18474 arg2Of 27,[
R99891 T6430 T18474 arg3Of ],[
R98220 T85453 T29393 arg1Of received,","
R79228 T79215 T77821 arg1Of patients,21
R3039 T79215 T5404 arg1Of patients,with
R31375 T75582 T5404 arg2Of COVID-19,with
R14004 T66055 T89299 arg1Of condition,whose
R84172 T75582 T89299 arg2Of COVID-19,whose
R52999 T66055 T80340 arg1Of condition,was
R29264 T44653 T80340 arg2Of or,was
R90654 T66055 T3490 arg1Of condition,severe
R25403 T3490 T44653 arg1Of severe,or
R81194 T55941 T44653 arg2Of critical,or
R78022 T66055 T55941 arg1Of condition,critical
R74963 T79215 T85453 arg1Of patients,received
R42123 T70238 T85453 arg2Of doses,received
R67132 T70238 T98598 arg1Of doses,one
R74424 T98598 T96881 arg1Of one,or
R53734 T24534 T96881 arg2Of two,or
R5731 T70238 T24534 arg1Of doses,two
R65601 T70238 T20616 arg1Of doses,of
R56743 T98192 T20616 arg2Of plus,of
R89899 T68912 T98192 arg1Of Tocilizumab,plus
R61440 T58005 T98192 arg2Of therapy,plus
R97353 T58005 T20706 arg1Of therapy,standard
R37793 T96625 T75572 arg1Of Patients,who
R91228 T96625 T31917 arg1Of Patients,had
R53068 T96963 T31917 arg2Of level,had
R75826 T96963 T15301 arg1Of level,a
R53187 T96963 T24848 arg1Of level,mean
R88261 T96963 T84688 arg1Of level,IL6
R96088 T96963 T6930 arg1Of level,of
R5373 T90933 T6930 arg2Of more,of
R57258 T90933 T81944 arg1Of more,than
R94369 T75581 T81944 arg2Of 100 pg/ml,than
R45661 T90933 T64021 arg1Of more,before
R79916 T84664 T64021 arg2Of treatment,before
R78642 T84664 T9387 arg1Of treatment,tocilizumab
R8185 T96625 T18203 arg1Of Patients,showed
R51850 T94537 T18203 arg2Of and,showed
R12091 T60803 T44490 arg1Of improvement,in
R66809 T14228 T44490 arg2Of symptoms,in
R61551 T14228 T81402 arg1Of symptoms,clinical
R5554 T60803 T94537 arg1Of improvement,and
R21619 T34900 T94537 arg2Of and,and
R92393 T35808 T83697 arg1Of saturation,peripheral
R24887 T35808 T13978 arg1Of saturation,oxygen
R90774 T35808 T34900 arg1Of saturation,and
R67692 T75964 T34900 arg2Of normalization,and
R62752 T34900 T84268 arg1Of and,for
R8244 T63070 T84268 arg2Of levels,for
R10896 T63070 T65028 arg1Of levels,lymphocyte
R57903 T63070 T34390 arg1Of levels,proportion
R97168 T34390 T96610 arg1Of proportion,and
R13130 T30755 T96610 arg2Of CRP,and
R88299 T63070 T30755 arg1Of levels,CRP
R81985 T1824 T31791 arg1Of absorbed,Also
R90910 T1824 T31152 arg1Of absorbed,","
R99138 T10130 T79595 arg1Of opacity,lung
R9904 T10130 T51431 arg1Of opacity,lesion
R90450 T10130 T31388 arg1Of opacity,was
R27294 T1824 T31388 arg2Of absorbed,was
R44975 T10130 T1824 arg2Of opacity,absorbed
R49421 T1824 T60055 arg1Of absorbed,in
R89954 T67288 T60055 arg2Of %,in
R85705 T67288 T38598 arg1Of %,90
R91084 T67288 T48683 arg1Of %,of
R76104 T41529 T48683 arg2Of patients,of
R22449 T98539 T69670 arg1Of nor,Neither
R42879 T98539 T9277 arg1Of nor,serious
R85183 T98539 T15021 arg1Of nor,adverse
R27191 T23626 T98539 arg1Of effects,nor
R64318 T65699 T98539 arg2Of deaths,nor
R37231 T98539 T50204 arg1Of nor,occurred
R56159 T50204 T20973 arg1Of occurred,with
R79941 T66286 T20973 arg2Of treatment,with
R50965 T66286 T14012 arg1Of treatment,tocilizumab
R66954 T24269 T26765 arg1Of There,are
R94262 T68003 T26765 arg2Of trials,are
R16905 T68003 T84711 arg1Of trials,ongoing
R34037 T68003 T74304 arg1Of trials,clinical
R29518 T68003 T5000 arg1Of trials,for
R26554 T83078 T5000 arg2Of treatment,for
R27449 T83078 T64198 arg1Of treatment,tocilizumab
R95470 T83078 T11331 arg1Of treatment,in
R78533 T42834 T11331 arg2Of patients,in
R30062 T42834 T27205 arg1Of patients,with
R17601 T27842 T27205 arg2Of COVID-19,with
R89241 T27842 T23786 arg1Of COVID-19,moderate
R28465 T23786 T45333 arg1Of moderate,and
R59576 T9137 T45333 arg2Of severe,and
R97104 T27842 T9137 arg1Of COVID-19,severe
R53041 T58078 T92236 arg1Of as,Currently
R61441 T58078 T32112 arg1Of as,","
R66943 T85855 T54987 arg1Of use,the
R89881 T85855 T69355 arg1Of use,of
R92489 T40115 T69355 arg2Of Tocilizumab,of
R4907 T85855 T10850 arg1Of use,is
R54223 T78367 T10850 arg2Of recommended,is
R26904 T85855 T78367 arg2Of use,recommended
R93944 T78367 T33042 arg1Of recommended,for
R96954 T36466 T33042 arg2Of patients,for
R92720 T36466 T61983 arg1Of patients,with
R61251 T2749 T61983 arg2Of COVID-19,with
R60119 T36466 T17580 arg1Of patients,who
R35135 T36466 T69055 arg1Of patients,have
R48731 T59356 T69055 arg2Of signs,have
R72772 T59356 T71996 arg1Of signs,warning
R6154 T59356 T65527 arg1Of signs,of
R22400 T44301 T65527 arg2Of inflammation,of
R13264 T44301 T99769 arg1Of inflammation,hyper
R72983 T78367 T54453 arg1Of recommended,","
R85482 T78367 T58078 arg1Of recommended,as
R94310 T53845 T58078 arg2Of measured,as
R71674 T85855 T75237 arg1Of use,can
R96842 T53845 T75237 arg2Of measured,can
R13154 T85855 T7496 arg1Of use,be
R84932 T53845 T7496 arg2Of measured,be
R87538 T85855 T53845 arg2Of use,measured
R19206 T53845 T78207 arg1Of measured,by
R40933 T36542 T78207 arg2Of and,by
R89076 T88455 T77671 arg1Of IL6,","
R2282 T67481 T77671 arg2Of ferritin,","
R15531 T77671 T99390 arg1Of ",",","
R60586 T65701 T99390 arg2Of counts,","
R8993 T65701 T23484 arg1Of counts,platelet
R92565 T99390 T30323 arg1Of ",",","
R21977 T81575 T30323 arg2Of markers,","
R92122 T81575 T72053 arg1Of markers,inflammatory
R15083 T36542 T96428 arg1Of and,","
R68271 T30323 T36542 arg1Of ",",and
R27501 T51141 T36542 arg2Of score,and
R83390 T51141 T88469 arg1Of score,H
R41615 T51141 T97739 arg1Of score,[
R59110 T29313 T97739 arg2Of 28,[
R77316 T54016 T97739 arg3Of ],[

LitCovid-sample-PD-MAT

Id Subject Object Predicate Lexical cue
T5 895-899 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung
T6 1893-1897 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung
T7 2324-2328 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T30 565-574 http://purl.obolibrary.org/obo/GO_0009058 denotes formation
T31 1428-1440 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T32 2672-2684 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T149 37-45 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T150 74-81 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T151 224-232 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T152 299-313 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T153 352-366 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T154 491-499 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T155 631-636 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T156 895-899 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T157 900-905 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T158 1101-1109 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T159 1360-1369 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T160 1518-1526 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T161 1608-1616 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T162 1663-1667 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T163 1893-1897 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T164 2280-2290 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T165 2324-2328 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T166 2723-2731 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T146 160-169 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096
T147 170-179 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T148 441-445 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T149 452-456 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T150 586-590 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T151 645-649 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T152 800-804 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T153 811-815 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T154 995-999 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T155 1015-1019 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T156 1055-1059 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T157 1066-1070 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T158 1269-1273 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T159 1428-1440 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T160 1572-1591 Disease denotes autoimmune diseases http://purl.obolibrary.org/obo/MONDO_0007179
T161 1635-1655 Disease denotes rheumatoid arthritis http://purl.obolibrary.org/obo/MONDO_0008383
T162 1657-1677 Disease denotes giant cell arteritis http://purl.obolibrary.org/obo/MONDO_0008538
T163 1679-1722 Disease denotes polyarticular juvenile idiopathic arthritis http://purl.obolibrary.org/obo/MONDO_0018456
T164 1739-1768 Disease denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/MONDO_0011429
T165 1898-1904 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T166 1942-1950 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T167 1987-1995 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T168 2554-2562 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T169 2631-2639 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T170 2672-2684 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T9 1572-1591 Phenotype denotes autoimmune diseases http://purl.obolibrary.org/obo/HP_0002960
T10 1635-1655 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T11 1668-1677 Phenotype denotes arteritis http://purl.obolibrary.org/obo/HP_0012089
T12 1693-1722 Phenotype denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/HP_0005681
T13 1739-1768 Phenotype denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/HP_0005681

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T26 565-574 http://purl.obolibrary.org/obo/GO_0009058 denotes formation
T27 1428-1440 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T28 2672-2684 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T26 565-574 http://purl.obolibrary.org/obo/GO_0009058 denotes formation
T27 1428-1440 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T28 2672-2684 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T164 0-51 Sentence denotes 6 Development of a human monoclonal antibody (mAb)
T165 53-81 Sentence denotes 6.1 Targeting the S protein
T166 83-101 Sentence denotes 6.1.1 Hypothesis:
T167 102-179 Sentence denotes A mAb against the binding domain of the virus can inhibit SARS-CoV2 infection
T168 180-466 Sentence denotes Recently, hybridoma supernatants containing antibody repertoires from immunized transgenic mice that express the human immunoglobulin heavy and light chains and rat origin immunoglobulin constant regions were used to detect antibodies that can cross neutralize SARS-S and SARS-2-S [26].
T169 467-687 Sentence denotes One chimeric 47D11 H2L2 antibody displayed such a cross-neutralizing activity, decreased syncytia formation induced by SARS-S and SARS2-S, and could protect VeroE6 cells against SARS-S and SARS2-S pseudotyped virus [26].
T170 688-820 Sentence denotes It may lie in its similar affinities for interacting with the same domain of the S1 subunit, i.e., S1B, of each SARS-S and SARS-2-S.
T171 822-838 Sentence denotes 6.1.2 Rational:
T172 839-923 Sentence denotes The chimeric 47D11 H2L2 might not be effective in human lung cells as it is in vitro
T173 924-1024 Sentence denotes 47D11 carried a higher affinity for interacting with the S2 subunit of SARS-S than that of SARS-2-S.
T174 1025-1206 Sentence denotes It is important that for both SARS-S and SARS-2-S, the binding of the 47D11 antibody to the target – the S1B domain – does not block the binding of S1B and S2 to ACE2 receptor [26].
T175 1207-1326 Sentence denotes By contrast, neutralizing antibodies that specifically target SARS-S could compete with S1B and S2 for binding to ACE2.
T176 1328-1369 Sentence denotes 6.2 Targeting pro-inflammatory cytokines
T177 1371-1389 Sentence denotes 6.2.1 Hypothesis:
T178 1390-1440 Sentence denotes A mAb against IL6 can attenuate hyper inflammation
T179 1441-1769 Sentence denotes Tocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis.
T180 1770-1851 Sentence denotes It is safe and effective for both adults and children two years of age and older.
T181 1853-1870 Sentence denotes 6.2.2 Rationale:
T182 1871-1950 Sentence denotes Tocilizumab can treat lung injury in patients with critical and severe COVID-19
T183 1951-2098 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 2099-2317 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 2318-2376 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 2377-2456 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.
T187 2457-2563 Sentence denotes There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19.
T188 2564-2779 Sentence denotes Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28].

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T9 1572-1591 Phenotype denotes autoimmune diseases http://purl.obolibrary.org/obo/HP_0002960
T10 1608-1633 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T11 1635-1655 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T12 1668-1677 Phenotype denotes arteritis http://purl.obolibrary.org/obo/HP_0012089
T13 1693-1722 Phenotype denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/HP_0005681
T14 1739-1768 Phenotype denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/HP_0005681